Quilience is a small molecule commercialized by NLS Pharmaceutics, with a leading Phase II program in Type 1 Narcolepsy (Narcolepsy with Cataplexy). According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Quilience’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Quilience is expected to reach an annual total of $8 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Quilience Overview

Mazindol ER is under development for the treatment of narcolepsy type 1 and Idiopathic hypersomnia (IH). The drug candidate is a small molecule which is administered through oral route. It was also under development for attention deficit hyperactivity disorder (ADHD) and restless legs syndrome (RLS). The drug candidate acts by targeting dopamine and norepinephrine reuptake and OX2R.

NLS Pharmaceutics Overview

NLS Pharmaceutics (NLS Pharma) is a drug development company that focuses on a strong scientific understanding of neurobehavioral and neurocognitive disorders and their pharmacognosy. NLS Pharma is headquartered in Stans, Switzerland.
The operating loss of the company was US$11.9 million in FY2021, compared to an operating loss of US$2.3 million in FY2020. The net loss of the company was US$12 million in FY2021, compared to a net loss of US$2.9 million in FY2020.

For a complete picture of Quilience’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.